Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Inclusion Criteria:

• Participants who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
• Participants who completed (or exited early from) the open-label Phase 4 ARGOS studywith no ongoing safety concerns, and received DURYSTA.

Exclusion Criteria:

• Female participants who are pregnant, nursing, or planning a pregnancy, or who are ofchildbearing potential and not using a reliable means of contraception during thestudy.
• Concurrent or anticipated enrollment in another investigational drug or device studyduring the present study.
• Any condition which would preclude the participant's ability to comply with studyrequirements, including completion of the study.
• Participants who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092.
• For patients from the ARGOS lead-in study: history of prior incisional glaucomasurgeries and/or minimally invasive glaucoma surgical procedures in the study eye ortreated fellow eye.